Chen Jichun, Ellison Felicia M, Keyvanfar Keyvan, Omokaro Stephanie O, Desierto Marie J, Eckhaus Michael A, Young Neal S
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1202, USA.
Exp Hematol. 2008 Oct;36(10):1236-43. doi: 10.1016/j.exphem.2008.04.012. Epub 2008 Jun 17.
To test function of hematopoietic stem cells (HSCs) in vivo in C57BL/6 (B6) and Trp53-deficient (Trp53 null) mice by using two HSC enrichment schemes.
Bone marrow (BM) Lin-CD41-CD48-CD150+ (signaling lymphocyte activation molecules [SLAM]), Lin-CD41-CD48-CD150- (SLAM-) and Lin-Sca1+CD117+ (LSK) cells were defined by fluorescence-activated cell staining (FACS). Cellular reactive oxygen species (ROS) level was also analyzed by FACS. Sorted SLAM, SLAM-, and LSK cells were tested in vivo in the competitive repopulation (CR) and serial transplantation assays.
SLAM cell fraction was 0.0078%+/-0.0010% and 0.0135%+/-0.0010% of total BM cells in B6 and Trp53 null mice, and was highly correlated (R2=0.7116) with LSK cells. CD150+ BM cells also contained more ROSlow cells than did CD150- cells. B6 SLAM cells repopulated recipients much better than B6 SLAM- cells, showing high HSC enrichment. B6 SLAM cells also engrafted recipients better than Trp53 null SLAM cells in the CR and the follow-up serial transplantation assays. Similarly, LSK cells from B6 donors also had higher repopulating ability than those from Trp53 null donors. However, whole BM cells from the same B6 and Trp53 null donors showed the opposite functional trend in recipient engraftment.
Both SLAM and LSK marker sets can enrich HSCs from B6 and Trp53 mice. Deficiency of Trp53 upregulates HSC self-renewal but causes no gain of HSC function.
通过两种造血干细胞(HSC)富集方案,在体内测试C57BL/6(B6)和Trp53基因缺陷(Trp53基因敲除)小鼠的造血干细胞功能。
通过荧光激活细胞染色(FACS)定义骨髓(BM)中Lin-CD41-CD48-CD150+(信号淋巴细胞激活分子[SLAM])、Lin-CD41-CD48-CD150-(SLAM-)和Lin-Sca1+CD117+(LSK)细胞。还通过FACS分析细胞活性氧(ROS)水平。分选后的SLAM、SLAM-和LSK细胞在体内进行竞争性再增殖(CR)和连续移植试验。
在B6和Trp53基因敲除小鼠中,SLAM细胞比例分别占总骨髓细胞的0.0078%±0.0010%和0.0135%±0.0010%,且与LSK细胞高度相关(R2 = 0.7116)。CD150+骨髓细胞中ROS低水平细胞也比CD150-细胞多。B6 SLAM细胞在再增殖受体方面比B6 SLAM-细胞好得多,显示出高HSC富集。在CR和后续连续移植试验中,B6 SLAM细胞在植入受体方面也比Trp53基因敲除的SLAM细胞好。同样,来自B6供体的LSK细胞比来自Trp53基因敲除供体的LSK细胞具有更高的再增殖能力。然而,来自相同B6和Trp53基因敲除供体的全骨髓细胞在受体植入方面显示出相反的功能趋势。
SLAM和LSK标记组均可从B6和Trp53小鼠中富集HSC。Trp53基因缺陷上调HSC自我更新,但不会导致HSC功能增强。